DEVEN JENNINGS: Open Payments
NPI 1699357913 · OREM, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,213 in 61 payments from 15 companies in 2025. Trend: 2023 $571 · 2024 $860 · 2025 $1,213
Food & beverage: $1,213
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $236 |
| Neurocrine BioSciences, Inc. | 7 | $176 |
| Vanda Pharmaceuticals Inc. | 6 | $165 |
| Alkermes, Inc. | 5 | $110 |
| Janssen Pharmaceuticals, Inc | 4 | $107 |
| Teva Pharmaceuticals USA, Inc. | 5 | $87 |
| Axsome Therapeutics, Inc. | 2 | $49 |
| Lundbeck LLC | 2 | $49 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $48 |
| Biogen, Inc. | 2 | $43 |
Products named: VRAYLAR, INGREZZA, FANAPT, SPRAVATO, REXULTI, ARISTADA, AUSTEDO XR, Auvelity.
Industry payments across UT — which companies pay providers there.
